Background: Vision loss is a rare but serious complication of facial hyaluronic acid (HA) filler injection, for which there is no proven rescue therapy. Retrobulbar hyaluronidase injection is advocated by many plastic surgeons as an emergency treatment, but has not been carefully assessed for its efficacy. Objectives: To evaluate the efficacy of retrobulbar hyaluronidase injection as a rescue treatment for vision loss caused by HA filler embolization. Methods: Patients with vision loss caused by HA filler embolization were treated with retrobulbar hyaluronidase injection. Their visual acuity and fundoscopic images before and after treatment were analyzed for efficacy assessment. Results: One patient with branch retinal artery occlusion (BRAO), one patient with posterior ischemic optic neuropathy (PION), one patient with ophthalmic artery occlusion, and one patient with both BRAO and PION were treated with one or two retrobulbar injections of 1500 or 3000 units hyaluronidase. No patients demonstrated substantial retinal artery recanalization or vision acuity improvement after treatment. Conclusions: One or two retrobulbar injections of 1500 to 3000 IU hyaluronidase are unable to recanalize retinal artery occlusion or improve the visual outcome of patients who presented with vision loss caused by HA filler embolization at least four hours after onset.
protocol improves visual prognosis better than predicted by the natural disease history. Only patients with ischemic optic neuropathy appear to benefit from very early and aggressive corticosteroid treatment. 9 Since hyaluronidase can rescue impending nasal skin necrosis associated with HA filler injection, 10 efforts have been made to deliver hyaluronidase to the ophthalmic circulation for the hydrolysis of HA emboli. One delivery technique is the direct injection of hyaluronidase into ophthalmic artery through selective angiography. Seven patients with HA filler-induced vision loss were treated this way, and two of them achieved partial ophthalmic artery recanalization. 2, 3 However, this technique demands an interventional facility and sophisticated skills, and thus is not widely available as a rescue treatment.
Another delivery technique is retrobulbar hyaluronidase injection, which is strongly advocated in the literature. 1, 11 This technique is feasible in theory because this enzyme has long been used safely as a spreading factor for ophthalmic regional blocks, 12 and an ex vivo study shows that hyaluronidase can hydrolyze HA filler transarterially. 13 Hu's group recently tried this method in one patient with PCAO, and the visual acuity improved slightly two weeks after treatment. 4 However, they failed to report the dose of retrobulbar hyaluronidase and the recanalization status of PCAO after treatment. Currently, there is no evidence that this technique is an effective rescue treatment for patients with HA filler-induced vision loss.
Here, we report the results of four patients who were treated with retrobulbar injections of high dose hyaluronidase. We carefully analyzed the temporal changes of their visual acuity and fundoscopic images before and after treatment.
METHODS
The study was conducted from June 2015 to July 2016, with approval from the Institutional Review Board of Guangdong Second Provincial People's Hospital (Guangzhou City, China). All patients were clearly informed of the experimental nature of the retrobulbar hyaluronidase treatment, and each patient provided written informed consent. The injection technique is similar to that published. 11, 12 Briefly, a dedicated retrobulbar injection needle (25 gauge, 3.8 cm long) is inserted through the skin at the junction of lateral one-third and medial two-thirds of the infraorbital rim. The patient is instructed to rotate the globe toward the superior and medial direction, and the needle is advanced 1 to 2 cm along the inferior wall of the orbit. After crossing the equator of the globe, the needle is directed medially and cephalad toward the apex of the orbit. Once a negative blood aspiration is confirmed, 1500 or 3000 IU ovine testicular hyaluronidase (Shanghai First Biochemical Pharmaceutical Corporation, China) in 2.0 mL saline is slowly injected into the retrobulbar space. The needle is finally withdrawn, and the globe is gently compressed for one minute.
RESULTS
We treated four referral patients who had monocular vision loss associated with facial HA filler injections, using retrobulbar hyaluronidase injections. Table 1 summarizes their disease profiles and treatment courses. All patients were young (mean age, 27 years; range, 23-35 years) and lean (mean body mass index, 19 kg/m 2 ; range, 17-21 kg/m 2 ) females without any history of ophthalmic disease. They all had facial filler injections shortly before developing the vision loss. The filler injections were made with only HA filler, which had been injected for nose augmentation in three patients and for forehead augmentation in one patient. Three patients developed vision loss immediately after filler injection, and one patient started to experience blurred vision one hour after filler injection. The underlying pathologies of vision loss were BRAO and PION for patient I, BRAO for Patient II, OAO for Patient III, and PION for Patient IV. All patients presented with some blepheroptosis, and two patients also presented with ophthalmoplegia, consistent with oculomotor nerve palsy. The blepheroptosis and ophthalmoplegia all resolved in a few weeks after treatment. No patient had concomitant brain infarction. The median follow-up time of the patients was 7 weeks (range, 3-8 weeks).
Although patients I to III all presented with retinal artery occlusion with retinal opacity and edema, the underlying pathologies of their vision losses were different. Patient I (23-year-old female) presented with no light perception (NLP) in her left eye (OS) 32 hours after onset of blurred vision, which developed one hour after her nose augmentation with 2.0 mL HA filler. An initial fundus photogram revealed superonasal, superotemporal, and inferotemporal BRAOs with retinal opacity and edema in the distributions of these branch retinal arteries (BRA) ( Figure 1A ). The BRAOs affected about 40 percent of macular perfusion, but fovea appeared well perfused ( Figure 1A) , as confirmed by a subsequent fundus fluorescein angiogram (FFA) ( Figure 2C ). Because fovea is the structural basis of central visual acuity, the preservation of fovea perfusion was not consistent with the patient's complete blindness. PION was therefore suspected, in light of the facts that this patient presented with a persistent defect of afferent pupillary light reflex, and her ocular computed tomography (CT) with enhancement suggested that the thickness of the left optic disc and the diameter of the left intraorbital optic nerve were larger than those of the other eye. In addition, the patient developed optic disc opacity eight weeks afterwards (Figure 3 ), which confirmed PION as the fundamental cause of the complete loss of her left eye visual acuity. 9 Patient II (23-year-old female) presented with temporal BRAO in her right eye (OD) twelve hours after an injection rhinoplasty with 0.8 mL HA filler and immediate vision loss ( Figure 4A ). Her initial visual acuity was confined to perception of hand motion (HM) at a 5 cm distance. She was found to have cornea edema by slit lamp biomicroscopy (Supplemental Figure 1A , available as Supplementary Material at www.aestheticsurgeryjournal.com), retinal hemorrhage by fundus photography ( Figure 4A ), and macular edema by optical coherence tomography (OCT) ( Figure 4B ). The cornea edema and retinal bleeding were probably caused by prior aggressive and incorrect ocular massage, and they blocked the patient's vision initially. However, the underlying cause of her right Figure 6 ). We therefore believe that the underlying pathology of her vision loss was PION.
We treated these patients with one or two retrobulbar injections of 1500 or 3000 IU hyaluronidase, in addition to the standard conservative treatment protocol. 8 The rationale for choosing 1500 IU as our starting dose was that the highest concentration of hyaluronidase used for peribulbular regional block is 300 IU/mL, 12 and the total amount of hyaluronidase in 4.0 mL anesthetic solution is 1200 IU. In addition, the half-life of human hyaluronidase is about 30 min in the subcutaneous tissue of rodents, 14 and thus the initial dose of retrobulbar hyaluronidase injection should be at least 1200 IU, so that 300 IU hyaluronidase would remain active one hour afterwards, the same dose that degraded HA filler transarterially. 13 We therefore injected 1500 IU per session in three patients and doubled the dose for Patient III, who had a more severe condition.
The initial fundus photograms of Patients I-III revealed clear retinal artery occlusions, which made it possible for us to observe the therapeutic effect of retrobulbar hyaluronidase injection on retinal artery recanalization. The effect of this treatment on retinal artery recanalization is very disappointing. In Patient I, superonasal, superotemporal and inferotemporal BRAOs remained unchanged eight hours after the first retrobulbar injection of 1500 IU hyaluronidase ( Figure 1B, arrows) . The second retrobulbar injection of 1500 IU hyaluronidase only led to a very slow recovery of the diameters and fillings of the superonasal BRA and the inferior branch of the superotemporal BRA from three days to one week after treatment (Figures 2A and 2B , black arrows); other BRAOs remained unchanged (Figures 2A and  2B , white arrows). In Patient II, there was no relief of retinal opacity or BRAO one week after one retrobulbar injection of 1500 IU hyaluronidase ( Figure 5A ). In Patient III, only inferotemporal BRAO appeared to be recanalized one day after the first retrobulbar injection of 3000 IU hyaluronidase ( Figure 6B, arrows) . The second retrobulbar injection of 3000 IU hyaluronidase failed to generate additional BRAO recanalization ( Figure 6C ). FFA identified little improvement of retinal and choroidal perfusions one week after treatment (Supplemental Figure 5B) . Therefore, none of the three patients demonstrated substantial recovery of retinal artery patency and/or retinal perfusion within one day after treatment.
None of the four patients experienced visual acuity improvement because of retrobulbar hyaluronidase injection. In fact, the visual acuity of Patient IV deteriorated from 20/200 to NLP OS sixteen hours after treatment ( Figure 8C ). The visual acuity of Patient II improved from HM/5 cm to 20/60 OD two weeks after treatment; however, the treatment most likely made no contribution to this partial recovery of visual acuity, because it coincided with the resolution of cornea edema (Supplemental Figure 1B) and the gradual absorption of retinal hemorrhage ( Figures  5A and 5B) , both of which blocked visual pathway initially. In addition, this eye still suffered from peripheral and inferonasal central visual field defects two and six weeks after treatment (Supplemental Figure 2) . The diseased right eye displayed delayed pattern VEP responses at lower amplitudes than the left eye did two weeks after treatment (Supplemental Figure 3) . The right eye also generated a flatter electroretinal response than the left eye did in response to the same visual stimuli six weeks after treatment (Supplemental Figure 4) . These data point to ischemic retinal injury that the retrobulbar hyaluronidase failed to salvage.
DISCUSSION
Vision loss caused by HA filler embolism is a medical emergency for which there is no proven rescue treatment. Although retrobulbar injection of hyaluronidase is strongly advocated by many physicians as a potential rescue treatment, 1,11 its efficacy remains unknown. In this study, four patients who presented with HA filler-induced BRAO, OAO, and/or PION at least four hours after the onset of vision loss were treated with retrobulbar injection of high dose hyaluronidase, and no patient demonstrated substantial retinal artery recanalization or visional acuity improvement. This questions the efficacy of this treatment among patients with HA-induced vision loss that lasts at least four hours.
Facial HA filler injection presumably causes vision loss through retrograde embolism. 5, 6 By this mechanism, filler particles are accidentally injected into the orbital branches of ophthalmic artery (supratrochlear, dorsal nasal, or supraorbital artery) or into the branches of facial or superficial temporal arteries that communicate with the ophthalmic artery system. The high pressure injection pushes the filler particles against the blood stream to the trunk of the ophthalmic artery. When the injection stops, the HA particles are carried by the blood stream to occlude the ocular branches of the ophthalmic artery, such as the CRA, PCA, and various arteries that nourish the posterior optic nerve. The CRA is a terminal branch of the ophthalmic artery that nourishes the inner layer of the retina, while the PCA branches of the ophthalmic artery directly supply blood to the choroid, outer layer of the retina, and the anterior part of the optic nerve. 8, 9, 15 The posterior part of the optic nerve derives its blood supply from various sources other than the PCA. 9 Because the retina, choroid and optic nerve are all critical for vision, the occlusion of their supplying arteries by the HA filler leads to various types of vision loss.
The CRA is a terminal artery that supplies the inner retina through its four major BRAs. There is little collateral circulation for the CRA except the cilioretinal artery found in some individuals. 8, 15 This makes the inner retina particularly vulnerable to ischemia and necrosis following retinal artery occlusion. In rhesus monkey, the retina only tolerates up to 97 min of CRA clamping without causing detectable injury, and four hours of complete CRA occlusion results in massive irreversible retinal injury. 16 This time window was found to be as long as 15 hours in human patients with CRAO caused by fibrinoplatelet embolization, particularly when incomplete CRAO was involved. 8, 17 However, it is very likely that soft HA gel particles cause total or subtotal CRAO and an effective rescue treatment needs to be initiated within four hours, and must be able to substantially recanalize HA occlusions and restore ophthalmic perfusion within four hours, if that treatment is to improve the visual outcome of patients with vision loss caused by HA filler embolization.
Hyaluronidase is an effective rescue treatment for impending nasal skin necrosis caused by HA filler embolization. 10 To recanalize the HA embolization in the ophthalmic artery system, hyaluronidase must be delivered to the vicinity of the HA emboli using various delivery techniques. The most efficient technique is the direct infusion of hyaluronidase into the ophthalmic artery using selective angiography. 2, 3 However, this interventional treatment demands a highly specialized facility, instruments, and skills that are not readily available to most physicians and patients. The other potential delivery option is retrobulbar hyaluronidase injection. 1, 4, 11 Ophthalmologists have long been using hyaluronidase as a spreading factor for retrobulbar or peribulbar regional blocks. 12 With proper training, plastic surgeons and dermatologists should be able to utilize this simple, fast, and well-established procedure for the rescue treatment of patients with vision loss caused by HA filler embolism.
The rationale behind retrobulbar hyaluronidase treatment is that the ophthalmic artery, CRA, PCA, and the arteries of the posterior optic nerve course through the retrobulbar space, which is located posterior to the globe and within the extraocular muscle cone. 11, 15 Because hyaluronidase degrades HA filler transarterially, 13 it is expected that retrobulbarly injected hyaluronidase will cross the walls of these arteries and enter the ophthalmic circulation. The enzyme would then be carried by the blood to the branches of the ophthalmic artery that are occluded by HA emboli. The direct contact of hyaluronidase with HA occlusion would allow the enzyme to hydrolyze the HA emboli, and restore the perfusions of ischemic retina, choroid or optic nerve. It is not clear whether hyaluronidase can penetrate human sclera and reach the choroid and retina. The feasibility of this treatment was recently tested in one patient with vision loss caused by the embolization of PCA by HA filler. 4 However, this study did not report the exact dose of retrobulbar hyaluronidase injection and failed to follow the patient using fundoscopic imaging techniques. There is an urgent need to determine the effect of retrobulbar hyaluronidase injection on retinal artery recanalization and patient's visual outcome.
In this study, we had a rare opportunity to treat four patients with vision loss associated with facial HA filler injection. The fundus photograms of three of these patients showed clear retinal artery occlusions ( Figures 1A,4A , and 6A), which allowed us to explore the recanalization effects of retrobulbar hyaluronidase treatment. However, this treatment was unable to substantially recanalize retinal artery occlusion for any patient within four hours. One retrobulbar injection of 1500 IU hyaluronidase failed to recanalize any BRAO for Patients I and II within eight hours (Figures 1 and 5) . A second retrobulbar injection of 1500 IU hyaluronidase for Patient I only gradually and slightly opened up some BRAOs in a few days, while the major BRAOs remained unchanged (Figure 2) . A very similar phenomenon was also found in Patient III, for whom one retrobulbar injection of 3000 IU hyaluronidase just recanalized one branch of the CRA in one day, without any apparent relief of global retinal opacity and edema ( Figure 6B) . A second retrobulbar injection of 3000 IU hyaluronidase made no further improvement of retinal perfusion ( Figure 6C ). These results suggest that one or two retrobulbar injections of 1500 to 3000 IU hyaluronidase are not fast and effective enough to meet the requirements of a rescue treatment, namely recanalyzing the retinal artery occlusion within four hours.
This recanalization failure could not be attributed to an insufficient dose of hyaluronidase. The half-life of this enzyme is about 30 min in the subcutaneous tissues of rodents. 14 If that is also the case for the enzyme in human retrobulbar space, there will be at least 325 IU hyaluronidase active one hour after one retrobulbar injection of 1500 IU hyaluronidase (Patients I and II). Patient III was retrobulbarly injected with 3000 IU hyaluronidase, while Patient IV received two retrobulbar injections, 1500 IU hyaluronidase each, separated by one hour. Both patients were expected to have more than 325 IU active hyaluronidase two hours after treatment. This amount of enzyme is greater than the 300 IU bovine testicular hyaluronidase that degraded HA filler across a fresh cadaveric facial artery within four hours. 13 Therefore, our patients had more than enough active hyaluronidase at the retrobulbar space for greater than one or two hours, able to enter the ophthalmic circulation to digest HA emboli.
The retinal artery recanalization likely failed because hyaluronidase is unable to efficiently permeate into the ocular branches of the ophthalmic artery and reach the HA emboli. It is very likely that the ophthalmic artery and its branches in a living patient are much less permeable to hyaluronidase than a cadaveric facial artery. 13 It is also possible that there is blood stasis in occluded ophthalmic artery branches, and hyaluronidase is unable to reach the distal HA emboli once it crosses the arterial wall into the ophthalmic artery system. There are many hyaluronidase inhibitors in human blood, and the half-life of hyaluronidase is 3.2 min in human serum. 14, 18 It is likely that hyaluronidase is quickly inactivated once it crosses the arterial wall and enters the ophthalmic circulation. To ensure there is sufficient amount of active hyaluronidase in the ophthalmic circulation to hydrolyze HA emboli, the enzyme needs to be constantly delivered into the ophthalmic artery system. Because repeated retrobulbar injections carry the inherent risk of ocular perforation, 12 retrobulbar injection may be a poor delivery technique of hyaluronidase. Direct infusion of hyaluronidase into the ophthalmic artery through selective angiography would be a more effective approach.
The fourth possibility for the recanalization failure is that secondary thrombosis might develop soon after HA embolization, requiring both hyaluronidase and a fibrinolytic drug for treatment. This possibility is supported by the observation that HA filler-induced rat inferior epigastric artery obstruction is more effectively recanalized by the intravenous infusion of both hyaluronidase and urokinase than by hyaluronidase infusion alone. 19 However, clinical studies do not support this concept. 2, 3 Korean ophthalmologists found that the injection of high dose (9000 IU) hyaluronidase into the ophthalmic artery partially recanalized OAO in one patient, while low dose (1500 IU) hyaluronidase plus urokinase did not always partially recanalize OAOs. This result suggests that hyaluronidase treatment remains the most critical, and the dose probably needs to be very high, since the half-life of this enzyme in blood is very short. 14, 18 However, further increasing the dose and/ or frequency of retrobulbar hyaluronidase injections may not be an option, because of the unforeseeable risk to the optic nerve or surrounding ocular tissues.
This lack of visual acuity improvement among our patients after retrobulbar hyaluronidase injection is not unexpected considering the poor recanalization effect of this treatment. The first three patients presented 32, 12, and 34 hours, respectively, after the onset of vision loss, much longer than the four hours of retinal survival time identified in rhesus monkey. 16 Their inner retina and/or posterior optic nerve probably had developed irreversible ischemic injury before any treatment could make a difference. Patient IV, who received retrobulbar hyaluronidase treatment four hours after the onset of vision loss, could have benefited from the reperfusions of the optic nerve; however, the hyaluronidase treatment failed to rescue the vision even when Patient IV had residual visual acuity (20/200 OS). Hu's group recently treated a patient seven hours after HA filler-induced PCAO using one retrobulbar injection of an unknown dose hyaluronidase. 4 The visual acuity improved from NLP to HM OD; however, this effect was observed two weeks after treatment, suggesting that this treatment made no contribution to the visual acuity improvement. Therefore, retrobulbar hyaluronidase injection has not been found to be effective in improving the visual outcome of patients who present at least four hours after the onset of vision loss caused by HA embolism. This study is limited by a small number of patients without a control group, since vision loss is a rare complication of facial filler injection. This study is also limited by the fact that most of our patients received retrobulbar hyaluronidase treatment much longer than four hours after the onset of vision loss, which severely limits the effect of this treatment in rescuing the patient's visual outcome. This study does not rule out the possibility that patients who receive retrobulbular hyaluronidase within four hours after filler injection benefit visually from this treatment. The exact answer awaits future studies. It is worthy of note that retrobulbar injection itself and hyaluronidase may cause serious complications, 12 and due precaution should be exercised. It is not clear why the visual acuity of Patient IV worsened from 20/200 to NLP OS sixteen hours after retrobulbar hyaluronidase treatment, which does suggest that this treatment is not without risk.
CONCLUSIONS
One or two retrobulbar injections of 1500 to 3000 IU hyaluronidase are unable to recanalize retinal artery occlusion or improve the visual outcome of patients who presented with vision loss caused by HA filler embolization at least four hours after onset.
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